Looking to the future in the treatment of steroid-refractory chronic GvHD

touchFOCUS for touchONCOLOGY

In this concise interview, Dr Corey Cutler discusses unmet needs in steroid-refractory chronic GvHD and how they may be addressed with new and emerging therapies.

The expert:

• Dr Corey Cutler - Dana-Farber Cancer Institute, Boston, MA, USA
  

This touchPODCAST is for HCPs outside the UK. 

This activity is funded by an independent medical education grant from Sanofi US.

This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchoncology.com